Related Experiment Video
Updated: May 14, 2026
11:49
Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
Axillary lymph node dissection in sentinel node positive breast cancer: is it necessary?
1Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan.
Current Opinion in Obstetrics & Gynecology
|February 22, 2013
Summary
Sentinel lymph node biopsy (SLNB) is standard for node-negative patients. For those with positive SLNB, axillary lymph node dissection (ALND) may not be necessary if one or two nodes are affected, improving breast cancer treatment.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Research
Background:
- Sentinel lymph node biopsy (SLNB) is the standard for axillary staging in node-negative breast cancer patients.
- Historically, positive SLNB results led to completion axillary lymph node dissection (ALND).
Purpose of the Study:
- To review the current evidence and define conditions under which ALND can be omitted after a positive SLNB.
- To evaluate the necessity of ALND in specific patient subgroups based on recent clinical trial data.
Main Methods:
- Review of clinical trials, focusing on the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial.
- Analysis of survival outcomes comparing SLNB alone versus SLNB plus ALND in patients with positive sentinel nodes.
Main Results:
- The ACOSOG Z0011 trial found no survival disadvantage for patients with one or two positive sentinel lymph nodes who did not undergo completion ALND.
- Patients with limited positive sentinel nodes (1-2) appear to be treated safely with SLNB alone, especially when undergoing breast-conserving surgery and radiation.
Conclusions:
- Axillary lymph node dissection may not be mandatory for all breast cancer patients with one or two positive sentinel lymph nodes.
- Further data from ongoing trials (e.g., AMAROS, IBCSG 23-01) are anticipated to refine guidelines on ALND omission.
